Parameters for using mannan-MUC1 fusion protein to induce cellular immunity

Cancer Immunology Immunotherapy

Volumn 45, Issue 6, 1998, Pages 321-326

  Pietersz, Geoffrey A ^a   Li, Wenjun ^a   Popovski, Violeta ^a   Caruana, Julie Anne ^a   Apostolopoulos, Vasso ^a   McKenzie, Ian F C ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

Adjuvants; Breast cancer; MFP; MUC1; Mucin1; Vaccine

Indexed keywords

FREUND ADJUVANT; HYBRID PROTEIN; MANNAN; MUCIN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; INTRADERMAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRECURSOR; PRIORITY JOURNAL; TUMOR IMMUNITY;

ANIMALS; CA-15-3 ANTIGEN; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG ADMINISTRATION ROUTES; GLYCOCONJUGATES; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION SCHEDULE; MANNANS; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0031934949     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050449     Document Type: Article

References (24)

1. Acres B, Hareuveni M, Balloul JM, Kieny MP (1993) Vaccinia virus MUC1 mmunization of mice: immune response and protection against the growth of murine tumors bearing the MUC1 antigen. J Immunother 14:136
2. Apostolopoulos V, McKenzie IFC (1994) Cellular mucins - targets for immunotherapy. Crit Rev Immunol 14:293
3. Apostolopoulos V, Xing PX, Trapani JA, McKenzie IFC (1993) Production of anti-breast cancer monoclonal antibodies using a glutathione-S-transferase-MUC1 bacterial fusion protein. Br J Cancer 67:713
4. Apostolopoulos V, Xing PX, McKenzie IFC (1994) Murine immune response to cells transfected with human MUC1: immunisation with cellular and synthetic antigens. Cancer Res 54:5186
5. Apostolopoulos V, Loveland BE, Pietersz GA, McKenzie IFC (1995) CTL in mice immunised with human Mucin 1 are MHC-restricted. J Immunol 155:5089
6. Apostolopoulos V, Pietersz GA, Loveland BE, Sandrin MS, McKenzie IFC (1995) Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc Natl Acad Sci USA 92:10128
7. Apostolopoulos V, Pietersz GA, McKenzie IFC (1996) Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 14:930
8. Bozeman PM, Hoidal JR, Shepherd VL (1988) Oxidant-mediated inhibition of ligand uptake by the macrophage mannose receptor. J Biol Chem 263:1240
9. Durrant LG, Buckley DJ, Spendlove I, Robins RA (1997) Low doses of 105AD7 cancer vaccine preferentially stimulate antitumor T-cell immunity. Hybridoma 16:23
10. Fazekas de St. Groth S (1982) The evaluation of limiting dilution assays. J Immunol Methods 49:R11
11. Fendly BM, Kotts C, Vetterlein D, Lewis GD, Winget M, Carver ME, Watson SR, Sarup J, Saks S, Ullrich A, et al (1990) The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer. J Biol Response Mod 9:449
12. Hird V, Maraveyas A, Snook D, Dhokia B, Soutter WP, Meares C, Stewart JS, Mason P, Lambert HE, Epenetos AA (1993) Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 68:403
13. + T helper cell phenotype development in a cell receptor-αβ-transgenic model. J Exp Med 182:1579
14. + T cells: specificity and function. Immunol Rev 101:39
15. Lefkovits I, Waldmann H (1984) Limiting dilution analysis of the cells of the immune system. I. The clonal basis of the immune response. Immunol Today 5:265
16. Maeurer MJ, Storkus WJ, Kirkwood JM, Lotze MT (1996) New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res 6:11
17. McKenzie IFC, Xing PX (1990) Mucins in breast cancer: recent immunological advances. Cancer Cells 2:75
18. Sarin PS, Mora CA, Naylor PH, Markham R, Schwartz D, Kahn J, Heseltine P, Gazzard B, Youle M, Rios A, Goldstein AL (1995) HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice. Cell Mol Biol 41:401
19. Stewart JS, Hird V, Snook D, Sullivan M, Hooker G, Courtenay-Luck N, Sivolapenko G, Griffiths M, Myers MJ, Lambert HE, Munro AJ, Epenetos AA (1989) Intraperitoneal radioimmunotherapy for ovarian cancer:pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies. Int J Radiat Oncol Biol Phys 16:405
20. Takada H, Kotani S (1995) Muramyl dipeptide and derivatives, In: Stewart-Tull, DES (eds) The theory and practical application of adjuvants. Wiley, Chichester
21. Taswell C (1981) Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol 126:1614
22. Tilkin AF, Lubin R, Soussi T, Larar V, Janin N, Mathieu MC, Lefrere I, Carlu C, Roy M, Kayibanda M, Bellet D, Guillet JG, Bressacdepaillerets B (1995) Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol 25:1765
23. Wreschner DH, Hareuveni M, Tsarfaty I, Smordinsky N, Horev J, Zaretsky J, Kotkes P, Weiss M, Lathe R, Dion A, Keydar I (1990) Human epithelial tumor antigen cDNA sequences: differential splicing may generate multiple protein forms. Eur J Biochem 189:463
24. Xing PX, Apostolopoulos V, Michaels M, Prenzoska J, Bishop J, McKenzie IFC (1995) Phase I study of synthetic MUC1 peptides in cancer. Int J Oncol 6:1283